In this week’s Pharma Phriday (April 17, 2026): In the clinic, some of the hardest-to-treat cancers are finally yielding ground, with survival data that would have been difficult to imagine a few years ago. Rare and underserved oncology and dermatology indications are also seeing regulatory progress. On the deals side, ADCs continue to attract serious investment, AI partnerships are expanding well beyond drug discovery into core business operations, and radiopharma is drawing

Lenacapavir from Gilead Sciences has shown promise when dosed even more widely apart - only once a year...

We've had our Eyes On recent data releases, commercial strategy updates, and some FDA updates. What caught your Eye last week?

Some of the highlights include AI medical advancements, strategic industry movements, regulatory updates, & challenges within the pharma ...